[HTML][HTML] Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations
D Omran, M Alboraie, RA Zayed, MN Wifi… - World journal of …, 2018 - ncbi.nlm.nih.gov
Worldwide, more than one million people die each year from hepatitis C virus (HCV) related
diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt …
diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt …
[HTML][HTML] Antiviral PROTACs: Opportunity borne with challenge
J Liang, Y Wu, K Lan, C Dong, S Wu, S Li, HB Zhou - Cell Insight, 2023 - Elsevier
Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …
Targeted protein degradation: advances in drug discovery and clinical practice
G Zhong, X Chang, W Xie, X Zhou - Signal Transduction and Targeted …, 2024 - nature.com
Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in
disease management, providing a stark contrast to traditional therapeutic approaches like …
disease management, providing a stark contrast to traditional therapeutic approaches like …
Performance of acoustic radiation force impulse elastography for staging liver fibrosis in patients with chronic hepatitis C after viral eradication
SH Chen, HC Lai, IP Chiang, WP Su… - Clinical Infectious …, 2020 - academic.oup.com
Background Data on noninvasive liver fibrosis staging after viral eradication are unclear.
This histology-based study validated the performance of liver stiffness (LS) measurements …
This histology-based study validated the performance of liver stiffness (LS) measurements …
Protective role of ITPA rs1127354-CA polymorphism against anemia in HCV patients using sofosbuvir ribavirin therapy: age and gender match case-control study
Background: Hepatitis C virus is affecting around 80 million people. Sofosbuvir ribavirin-
based therapy is associated with certain side effects, especially anemia. Inosine …
based therapy is associated with certain side effects, especially anemia. Inosine …
[HTML][HTML] Impact of gender difference on characteristics and outcome of chronic hepatitis C
M Saif-Al-Islam, HS Mohamed, MA Younis… - Open Journal of …, 2020 - scirp.org
Gender difference in chronic hepatitis C (CHC) infection is not previously well studied. We
aimed to analyze the effect of gender difference on the risk factors of CHC, disease …
aimed to analyze the effect of gender difference on the risk factors of CHC, disease …
Clinical relevance of serum non‐organ‐specific antibodies in patients with HCV infection receiving direct‐acting antiviral therapy
E Shahini, A Iannone, D Romagno… - Alimentary …, 2018 - Wiley Online Library
Summary Background Hepatitis C virus (HCV) infection is associated with production of
different serum non‐organ‐specific antibodies (NOSA) and risk for developing autoimmune …
different serum non‐organ‐specific antibodies (NOSA) and risk for developing autoimmune …
[PDF][PDF] 慢性丙型肝炎合并肾脏疾病的研究进展
罗雪艳， 李莉， 关瀛， 邓婷婷， 秦坤 - 新医学, 2021 - xinyixue.cn
丙型肝炎病毒(HCV) 感染导致的肝外损害以肾损伤多见, 同时慢性肾脏病发展到终末期肾病行
血液透析时可增加HCV 感染风险. 慢性丙型肝炎合并肾脏疾病可加速疾病的进程 …
血液透析时可增加HCV 感染风险. 慢性丙型肝炎合并肾脏疾病可加速疾病的进程 …
Comparison between the effect of two regimens for hepatitis C treatment (Qurevo and ribavirin) and (sofosbuvir, daclatsvir and ribavirin) on patients above and below …
MAEM Othman, AEL Mawjood… - … Egyptian Journal of …, 2018 - ejhm.journals.ekb.eg
Background: the goal of antiviral treatment is to prevent complications of the disease, mainly
cirrhosis and HCC. New therapy options, known as direct acting antiviral (DAA) regimens …
cirrhosis and HCC. New therapy options, known as direct acting antiviral (DAA) regimens …